Martelli M, Cardillo G, Lopergolo M, Facciolo F
Divisione di Chirurgia Toracica, Ospedale C. Forlanini, Roma.
Chir Ital. 1995;47(3):30-3.
Experience during the past 10 years has shown up different opinions on the surgical treatment of patients with stage III non-small cell lung cancer. In the light of high resectability and survival rates (respectively 80.8% and 40% at 2 years in the experience of the Southwest Oncology Group) produced with neoadjuvant therapy (followed by surgery) it appears to be an appealing therapeutic option. Until recently, there have been no large prospective randomized phase III trials to answer the question of whether neoadjuvant therapy is superior to other treatment modalities (surgical resection alone; non-surgical treatment).
过去10年的经验显示，对于III期非小细胞肺癌患者的外科治疗存在不同观点。鉴于新辅助治疗（随后进行手术）所产生的高切除率和生存率（西南肿瘤协作组经验显示2年时分别为80.8%和40%），它似乎是一个有吸引力的治疗选择。直到最近，尚无大型前瞻性随机III期试验来回答新辅助治疗是否优于其他治疗方式（单纯手术切除；非手术治疗）这一问题。
